11 February 2025
11 February 2025
A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the general population.
Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease space.
Three Phase III trials are currently underway investigating abelacimab for arterial and venous clots.
Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.
The approval is based on the findings from a multicentre, double-blind Phase III trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
